SynAct Pharma AB (STO: SYNACT)
Sweden
· Delayed Price · Currency is SEK
8.81
-0.19 (-2.11%)
Nov 18, 2024, 12:14 PM CET
SynAct Pharma AB Statistics
Total Valuation
SynAct Pharma AB has a market cap or net worth of SEK 370.02 million. The enterprise value is 332.96 million.
Market Cap | 370.02M |
Enterprise Value | 332.96M |
Important Dates
The last earnings date was Wednesday, October 30, 2024.
Earnings Date | Oct 30, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
SynAct Pharma AB has 41.30 million shares outstanding. The number of shares has increased by 22.54% in one year.
Current Share Class | n/a |
Shares Outstanding | 41.30M |
Shares Change (YoY) | +22.54% |
Shares Change (QoQ) | +4.79% |
Owned by Insiders (%) | 9.97% |
Owned by Institutions (%) | 6.23% |
Float | 24.03M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 2.19 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.15 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.88, with a Debt / Equity ratio of 0.01.
Current Ratio | 3.88 |
Quick Ratio | 3.42 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -41.01 |
Financial Efficiency
Return on equity (ROE) is -81.55% and return on invested capital (ROIC) is -24.48%.
Return on Equity (ROE) | -81.55% |
Return on Assets (ROA) | -18.93% |
Return on Capital (ROIC) | -24.48% |
Revenue Per Employee | n/a |
Profits Per Employee | -30.91M |
Employee Count | 5 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.12% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +35.12% |
50-Day Moving Average | 8.94 |
200-Day Moving Average | 8.02 |
Relative Strength Index (RSI) | 54.04 |
Average Volume (20 Days) | 74,216 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -74.69M |
Pretax Income | -161.05M |
Net Income | -154.57M |
EBITDA | n/a |
EBIT | -74.69M |
Earnings Per Share (EPS) | -4.08 |
Balance Sheet
The company has 38.49 million in cash and 1.43 million in debt, giving a net cash position of 37.06 million or 0.90 per share.
Cash & Cash Equivalents | 38.49M |
Total Debt | 1.43M |
Net Cash | 37.06M |
Net Cash Per Share | 0.90 |
Equity (Book Value) | 169.16M |
Book Value Per Share | 4.10 |
Working Capital | 47.18M |
Cash Flow
Operating Cash Flow | -91.81M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
SynAct Pharma AB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.54% |
Shareholder Yield | -22.54% |
Earnings Yield | -45.55% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |